Analytical Data
-
Gene name
PFS230
- Application
-
Species
Plasmodium falciparum
-
Source
E. coli
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P68874
-
Expression Region
2980-3116aa
-
Molecular Weight
15.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PFS230 is a recombinant protein derived from the Plasmodium falciparum parasite, which is the causative agent of the most severe form of malaria. Research on PFS230 has gained significant attention due to its potential role in malaria transmission-blocking strategies. Specifically, PFS230 is a part of the sexual stages of the parasite, and antibodies against this protein can inhibit the development of the malaria parasite within the mosquito vector, thereby reducing the transmission of the disease to humans. Understanding the immunogenicity and efficacy of PFS230 is critical for the development of innovative malaria vaccines aimed at interrupting the lifecycle of the parasite. Studies have shown that vaccination with PFS230 can elicit strong immune responses in animal models, and ongoing research seeks to elucidate the mechanisms by which these immune responses can be harnessed in human populations. Given the urgent global health burden posed by malaria, particularly in endemic regions, the exploration of PFS230 not only promises to contribute to vaccine development but also supports broader efforts to achieve malaria eradication. By advancing our knowledge of PFS230 and its interactions with the immune system, researchers aim to pave the way for novel immunological approaches that could significantly diminish malaria transmission rates and improve public health outcomes worldwide.
